Trappsol® Cyclo™

About Cyclo Therapeutics

Cyclo Therapeutics is a US-based biotech leveraging cyclodextrin chemistry to create novel treatments for challenging diseases, with its most advanced candidate, Trappsol® Cyclo™, in clinical development for Niemann-Pick Disease Type C. The company is expanding its pipeline to include Alzheimer's disease, aiming to address pathological protein aggregation. Founded in 2000, it operates as a public entity, driving programs from clinical trials towards potential regulatory approval. Its strategy centers on harnessing its proprietary drug delivery platform to improve therapeutic outcomes in underserved patient populations.

About Cyclo Therapeutics

Cyclo Therapeutics is a US-based biotech leveraging cyclodextrin chemistry to create novel treatments for challenging diseases, with its most advanced candidate, Trappsol® Cyclo™, in clinical development for Niemann-Pick Disease Type C. The company is expanding its pipeline to include Alzheimer's disease, aiming to address pathological protein aggregation. Founded in 2000, it operates as a public entity, driving programs from clinical trials towards potential regulatory approval. Its strategy centers on harnessing its proprietary drug delivery platform to improve therapeutic outcomes in underserved patient populations.

About Rafael Holdings

Rafael Holdings is a clinical-stage biotech focused on developing novel oncology and rare disease therapeutics. Its core mission is to improve and extend the lives of patients with difficult-to-treat diseases by targeting cancer metabolism and lysosomal function. The company's strategy leverages its lead asset, devimistat, in late-stage trials for solid tumors and hematologic malignancies, while integrating new platforms through strategic mergers. With two Phase 3 trials ongoing and a recent expansion into rare diseases, Rafael is transitioning from a clinical-stage entity toward a potential commercial enterprise.

Therapeutic Areas